Uma umdlavuza wesibindi oyinhloko uhlotshaniswa ne-ascites, i-jaundice, i-metastasis ekude, njll., kubizwa ngokuthi umdlavuza wesibindi oyinhloko. Ukwelashwa komdlavuza wesibindi oyinhloko kunzima, futhi umphumela wokwelapha emtholampilo awulungile. Ukuhlinzwa akuyona inketho yokwelapha umdlavuza wesibindi osuthuthukile ngoba ususabalele kuma-lymph nodes noma kwezinye izitho.
If the liver is in good condition (Child-Pugh grade A or B), the doctor will consider treatment with the targeted therapeutic drugs Sorafenib (Nexavar) or Lenvama (Lenvima). Growth can prolong the survival time of patients. If the patient develops drug resistance, the targeted drug repaglinide (Stivarga) or the immunotherapy drug nivolumab (Opdivo) can be used instead.
In addition, keeping an eye on clinical trial information at any time and actively participating in relevant clinical trials such as chemotherapy, radiotherapy, and immunotherapy may also bring opportunities and hope for patients with advanced umdlavuza wesibindi. It is hoped that in the next few years, researchers will make a huge breakthrough in the field of liver cancer diagnosis and treatment.
